Recursion Pharmaceuticals shows high cash burn, limited efficacy data, and unproven platform validation. Check out why RXRX ...
Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) stock is surging on Wednesday, without any news to justify the movement. Session volume stands at 69.3 million versus the average volume of 26.9 million, ...
In the latest close session, Recursion Pharmaceuticals (RXRX) was down 5.42% at $5.23. The stock fell short of the S&P 500, which registered a loss of 0.38% for the day. Meanwhile, the Dow experienced ...
In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...
Key data is currently not available. Data Disclaimer: The Nasdaq Indices and the Major Indices are delayed at least 1 minute. *Data is provided by Barchart.com. Data reflects weightings calculated at ...
Abstract: This article addresses the problem of secure recursive state estimation for a networked linear system, which may be vulnerable to interception of transmitted measurement data by ...
Abstract: In this article, recursive filtering is investigated for time-varying discrete sequential systems (DSSs) under weighted try-once-discard (WTOD) protocols, which are employed to govern the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback